Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 17/20 | 1.00 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28273229 | 0.83 | NOTUM (0.71) | NOTUM | |
| SCHEMBL21795694 | 0.82 | NOTUM (0.75) | NOTUM | |
| SCHEMBL6408072 | 0.79 | NOTUM (0.65) | NOTUMNPBWR1HTT | |
| SCHEMBL23451501 | 0.77 | NOTUM (1.00) | NOTUM | |
| SCHEMBL11232897 | 0.75 | NOTUM (0.74) | NOTUM | |
| SCHEMBL12360483 | 0.75 | NPC1 (0.63) | NOTUMNPC1HTTRAB9A | |
| SCHEMBL14452782 | 0.75 | KDM4E (0.66) | NOTUMNPC1HTTRAB9A | |
| SCHEMBL21776860 | 0.74 | NOTUM (1.00) | NOTUMNPC1RAB9A | |
| SCHEMBL942003 | 0.74 | NOTUM (0.64) | NOTUM | |
| SCHEMBL3794714 | 0.74 | NOTUM (0.64) | NOTUMNPC1HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287022-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-08-29 | — | — | US | disclosed |
| US-11634391-B2 | Compounds which are inhibitors of Notum | UCL BUSINESS LTD (GB) | 2023-04-25 | — | — | US | disclosed |
| EP-3843844-A1 | COMPOUNDS | UCL Business Ltd (GB) | 2021-07-07 | — | — | EP | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| WO-2020043866-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2020-03-05 | — | — | WO | disclosed |
| US-20050107616-A1 | Alpha-ketoamide derivatives as cathepsin k inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | NOTUM, GOT2, GOT1 | NOTUM 1/4885NPBWR1 1831/4885NPC1 51/4885 |
| US-20210171475-A1 | COMPOUNDS | GOT2, GOT1, OAT | NOTUM 5/4885NPBWR1 811/4885NPC1 7/4885 |
| US-20050107616-A1 | Alpha-ketoamide derivatives as cathepsin k inhibitors | CTSK, CTSE, CTSZ | NOTUM 1001/4885NPBWR1 2553/4885NPC1 662/4885 |
| US-20240287022-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL1RN | NOTUM 4288/4885NPBWR1 576/4885NPC1 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.